Business Wire

Xilam: Record 2017 Annual Results

Jaa

Regulatory News:

The Board of Directors of Xilam Animation S.A. (Paris:XIL) convened on 27 March 2018. The meeting, chaired by Marc du Pontavice, was held to review the consolidated financial statements as at 31 December 2017.

Consolidated income statement (in thousands of euros)   2017(1)   2017 restated(2)   2016   % chg.
New productions(3)   15,319       10,756   +42%
Catalogue   9,017       5,083   +77%
Other   62       39   +59%
Revenue   24,398       15,878   +54%
Other current operating income   2,174       1,263   +72%
Total operating income   26,572       17,141   +55%
Operating expenses   (18,940)       (12,851)   +47%
Other non-current operating income and (expenses)   -       16    
Operating income   7,632   8,663   4,306   +77%
Current operating margin   31.3%   35.5%   27.1%    
Net income   5,948   6,739   3,198   +86%
Net margin   24.4%   27.6%   20.1%    
(1) Audit underway        
(2) Operating income and net income restated for the impact of the bonus share award plans
(3) Including subsidies and development

Increased activity reveals the quality of the business model

Growing demand for Xilam’s new productions is a clear testament to the Group’s positioning. 2017 was a turning point in terms of the increased impact of Xilam’s business model.

Four factors are behind the sharp increase in income:

  • business activity that is growing more quickly than the cost structure;
  • increased value of new productions pre-sales is making a greater contribution to income;
  • the expansion of the catalogue is mitigating the pace at which series are amortised;
  • Xilam’s investment strategy allows it to retain almost 100% of the revenue from its productions.

This virtuous set-up demonstrates the strength of Xilam’s business model, which is beginning to have an impact on the Group’s financial results.

Xilam’s operating margin increased 77% to a record high of EUR 7.632 million, or 31.3% of revenues.

This published operating income figure includes the impact of the two bonus share award plans set up in 2016 and 2017, a portion of which has been provisioned in the year’s operating expenses.

Restated for the accounting impact of the expense associated with these two share plans and the related social security charges, operating income for 2017 would have totalled EUR 8.663 million, for an operating margin of 35.5%.

The Group’s net margin came out to 24.4%, with net income totalling EUR 5.948 million, an 86% increase on 2016.
The income tax expense of EUR 1.950 million includes a deferred tax expense in the amount of EUR 1.163 million, with no impact on cash assets.
Restated net income includes the restatement of the expense associated with the bonus share award plans and the related tax assets, and totalled EUR 6.739 million.

Global demand rising sharply

Xilam posted a 54% increase in revenue compared to last year, driven by substantial growth in New Productions and Catalogue revenue.

The Group benefits from a favourable price effect on both New Productions (+42% in value terms, +24% in volume) and the Catalogue segment (+77%). This is primarily due to increased competition between traditional (free or pay) television channels and digital platforms. Digital platforms now account for 23% of total revenue (compared to barely 8% three years ago) and 40% of Catalogue revenue.

The 21% increase in the number of video views on YouTube, the world’s leading video streaming platform, to 2.6 billion in 2017, is clear evidence of the global demand for the Group’s content.

Powerful drivers that will support our growth

With a solid structure and a production team that is appropriately sized to satisfy the demand from television channels and digital platforms, Xilam is ready to move to the next level.

As such, seven different shows are currently in production:

  • The fifth season of Oggy and the Cockroaches , which has been pre-purchased by Gulli in France and Cartoon Network internationally. With this new production, the Oggy brand will boast a total of 117 half-hour programmes produced in Ultra HD, thereby guaranteeing the brand’s global sustainability for several years to come. Deliveries will be completed in 2018.
  • The studio's first pre-school show, Paprika , an original new series pre-purchased by France Télévisions in France and by Disney abroad, with delivery to be completed in the first half of 2018.
  • The second season of Magic, bought by Gulli on the heels of a successful first season, with delivery to be completed in the first half of 2018.
  • Mr Magoo, adapted from the famous American series from the 1950s and 60s, went into production in early 2017, following the purchase of rights by France Télévisions and Cartoon Network for deliveries in 2018.
  • If I were an animal , a wildlife series designed especially for children, went into production in late 2016, following the purchase of rights by France Télévisions and Netflix for deliveries to be completed during the first quarter of 2018.
  • Coach me if you can , an original, football-themed creation from the Xilam studio that is expected to be released worldwide and will be launched to coincide with Euro 2020.
  • Season 3 of Zig & Sharko , which has already been pre-purchased by clients that subscribed to the previous seasons.

These series will enable Xilam to achieve its target of delivering 70 half-hour programmes in 2018, thereby confirming the solid progress of its operations. Xilam’s four studios (Paris, Lyon, Angoulême and Ho-Chi-Minh City) are now fully operational and well prepared to meet this target.

Other projects created in the Xilam studios will enter production in 2018. In particular, these include The Fabulous Adventures of Prince Moka and Tiny Bad Wolf , two original creations that will afford Xilam additional growth avenues in the coming years.

The Group is also continuing with its strategy of developing its catalogue income through merchandising revenues, drawing on the set-up of an agent network covering 75% of the world.

Chairman and CEO of Xilam, Marc du Pontavice, commented, “We are proud and delighted to be able to present these record results to our shareholders and investors. The relevance of the strategy adopted by Xilam for more than 15 years was confirmed in 2017, as was the virtuous circle achieved through original creations, management of the value chain and formats adapted to international markets and the digital sector.
Xilam’s unique positioning is the result of several long years of development, construction and investment.
With a stronger, more structured organisation and a buoyant economic backdrop, Xilam is now benefiting from all of its assets in order to continue its solid trend of growth and profitability.”

About Xilam

Xilam is one of Europe’s leading animation companies, creating, producing and distributing original children’s and family entertainment content across TV, film and digital media platforms.

Founded in 1995 by Marc du Pontavice, Xilam owns a catalogue of more than 2,000 animated episodes and three feature films including strong brands such as Oggy & the Cockroaches, Zig & Sharko, The Daltons and its first pre-school series, Paprika.

Broadcast in over 190 countries on all the major TV networks and digital platforms, in particular garnering over 2.6 billion views on YouTube in 2017, Xilam’s programme catalogue makes the company one of the top global content providers in animation.

Xilam employs more than 400 people, including 300 artists, who are based across its four studios located in Paris, Lyon, Angoulême and Ho-Chi-Minh City in Vietnam.

Xilam is listed on Compartment B of Euronext Paris
PEA-eligible
SRD long-eligible
ISIN code: FR0004034072 / Ticker: XIL

Contact information

Xilam
Marc du Pontavice – Chairman and CEO
François Bardoux – CFO
Tel: +33 1 40 18 72 00

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00Tiedote

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10Tiedote

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13Tiedote

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00Tiedote

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41Tiedote

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00Tiedote

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme